Related Experiment Video
Updated: May 9, 2026

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
[Application of propofol sedation in patients undergoing continuous venous-venous haemodiafiltration]
Hai-tao Zhang1, Shao-wen Cheng, Lei Peng
1Department of Emergency, Hospital of Hainan Medical University, Haikou 571102, Hainan, China.
Objective:
To study the use of propofol sedation in patients undergoing continuous venous-venous haemodiafiltration (CVVHDF) and assess the curative effects.
Methods:
A retrospective study was conducted. Data from 74 patients with continuous sedation of propofol in emergency intensive care unit (ICU) from April 2009 to June 2011 were analyzed. There were 26 cases suffering from acute renal failure in CVVHDF group and 48 critical cases in non-CVVHDF group. Propofol administration duration, dose, the clearance rate and the average recovery time in both groups were analyzed, and plasma concentrations of propofol at inflow side and outflow side of CVVHDF circuit in 26 patients with CVVHDF were determined.
Results:
Compared with non-CVVHDF group, it took a longer administration time (298.37±28.73 hours vs. 173.44±17.27 hours, P<0.05) and higher dose (35.89±0.76 g vs. 21.82±0.62 g, P<0.05) in CVVHDF group. There were no statistical significances on clearance rate at 2, 6, 24 hours after administration (2 hours: 13.85±1.15 ml/min vs. 14.41±1.21 ml/min, 6 hours: 5.92±0.52 ml/min vs. 6.32±0.59 ml/min, 24 hours: 4.75±0.41 ml/min vs. 5.33±0.45 ml/min) and recovery time (8.89±1.46 minutes vs. 8.47±1.37 minutes) between CVVHDF and non-CVVHDF groups (all P>0.05). Plasma concentrations of propofol at inflow side and outflow side of CVVHDF circuit were not different after propofol administration in 26 CVVHDF patients.
Conclusions:
Compared with patients in non-CVVHDF group, the patients who received propofol in CVVHDF required higher total dosage and longer delivery time to maintain a good sedation. In both two groups clearance rate of propofol and maintenance of a stable blood concentration were the same. The use of a proper dose of propofol in CVVHDF did not affect wake up time of the patients, there were no complications.
Related Concept Videos
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Continuous Renal Replacement Therapy
Hemodialysis II: Procedure and Complications
Parenteral Anesthetics: Overview
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
